Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Advair HFA (fluticasone propionate and salmeterol) is indicated for the treatment of asthma in adult and adolescent patients aged 12 years and older.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• HRQoL in Asthma (Moderate-to-Severe Asthma): FP/Sal demonstrated significant improvements in HRQoL, with a mean difference in AQLQ CFB of 0.65 compared to placebo, 0.58 versus LABA, and 0.21 against ICS alone. No significant differences were observed when compared to other ICS/LABA combinations (0.06) or ICS/formoterol MART (0.00).
• Pediatric Asthma (FP/SAL vs. FP/FORM): FP/SAL resulted in better pre-dose FEV₁, asthma symptom scores, and sleep disturbance scores, while FP/FORM showed superiority in PEFR. No significant differences were noted in 2-hour post-dose FEV₁ or other lung function parameters.
• COPD (LABA/LAMA vs. ICS/LABA): LABA/LAMA combinations, including umeclidinium/vilanterol, glycopyrronium/indacaterol, and glycopyrrolate/formoterol fumarate, were more effective than ICS/LABA combinations in improving trough FEV₁ and reducing the risk of COPD exacerbations.
• Regular use of formoterol/salmeterol combined with ICS did not show significant differences in mortality or non-fatal serious adverse events when comparing formoterol/budesonide and salmeterol/fluticasone. Few asthma-related serious adverse events were reported, leading to low confidence in the safety conclusions.
• In pediatric asthma, no significant differences in overall adverse events were observed between FP/SAL and FP/FORM, though FP/FORM was associated with a lower incidence of nasopharyngitis.
• The reviewed studies indicate that patients with moderate-to-severe asthma, pediatric asthma, chronic asthma in adults and adolescents, and moderate-to-severe COPD were the primary populations studied, with clinically relevant findings highlighting HRQoL improvements with FP/Sal in moderate-to-severe asthma, differing efficacy in lung function between FP/SAL and FP/FORM in pediatric asthma, comparable safety profiles in chronic asthma treatments, and superior efficacy of LABA/LAMA combinations over ICS/LABA in improving lung function and reducing exacerbations in COPD.